Introduction

Of the trauma-and stress-related disorders, post-traumatic stress disorder (PTSD) is the most prevalent and well-understood. It is triggered by exposure to acute or reoccurring traumatic events and characterized by four distinct symptom clusters: intrusive re-experiencing, avoidance, hyperarousal, as well as negative cognitions and mood (Diagnostic and Statistical Manual of Mental Disorders, 5th edition [DSM-5]). Accordingly, the major features of PTSD reflect deficits in stress- and fear memory–related mechanisms. In comparison...
with other trauma-related disorders, the epidemiological patterns of PTSD are fascinating—60% to 90% of Americans are exposed to PTSD risk factors, yet PTSD only manifests in 8% to 12% of the general population.\(^1\) Given the low disease penetrance, despite frequent exposure to environmental risk factors, it is both surprising and alarming that adult females exhibit a twofold higher lifetime prevalence of PTSD and greater symptom severity than males and prepubescent females.\(^2\)\(^-\)\(^5\) This incongruity within PTSD’s broader disease profile highlights the following: interindividual variability significantly negotiates PTSD risk, and one such variability, sex, differentially influences PTSD susceptibility, potentially via sex-dependent risk factors.\(^6\)\(^,\)\(^7\)

Many studies suggest that complex interactions between biological and environmental risk factors generate changes within neural substrates that regulate biological responsivity to trauma exposure.\(^6\) These intermediate phenotypes, in turn, promote maladaptive behavioral changes that manifest as PTSD-associated symptom clusters. Until recently, an overreliance on male cohorts in preclinical and clinical investigations has limited the field’s understanding of how biological and environmental risk factors shape PTSD vulnerability in a sex-dependent manner. However, a recent convergence of studies implicates the pituitary adenylate cyclase–activating polypeptide (PACAP)ergic system, a fear- and stress-regulating biological system, in shaping sex-dependent PTSD risk. These studies have provided insights into sex-specific biological and environmental sculptors of PTSD susceptibility, as well as predictive PTSD biomarkers that may be potentially used to more effectively diagnose and treat female PTSD patients. Below, we will examine the intersection between sex-specific PTSD risk factors and the PACAPergic system to determine how the two collaborate to differentially shape PTSD susceptibility in females. In doing so, we will demonstrate the interconnectivity of biological and environmental risk factors and how this intersection influences sex-specific PTSD etiology and symptomatology.\(^8\)

**Introduction to the PACAPergic system**

The PACAPergic system is a highly conserved biological system comprised of several polypeptides of varying sizes, owing to posttranslational proteolytic processing of the PACAP precursor protein that is encoded by the adenylate cyclase–activating polypeptide 1 gene (\(ADCYAPI\)).\(^9\)\(^,\)\(^10\) Two polypeptides, a 27- and a 38-amino-acid peptide (PACAP27 and PACAP38, respectively), are the most abundantly expressed and biologically active in the pituitary and in peripheral tissues, with PACAP38 being tenfold to 100-fold more abundant than PACAP27.\(^11\) Subsequent to the isolation of the PACAP38 gene, its three cognate receptors were identified and found to be highly expressed in the periphery and the brain.\(^12\) Of the three receptors, only the PACAP type 1 receptor (PAC1R) selectively binds PACAP27 and PACAP38 with high affinity.\(^13\)

The PAC1R is a G-protein coupled receptor which, upon PACAP binding, recruits either \(G_{q/11}\) and/or \(G_{q/12}\)-coupled second-messenger pathways.\(^10\)\(^,\)\(^14\) Alternative splice events in the N-terminal and third intracellular loop of the PAC1R transcript diversify PAC1R properties, such as ligand affinity and coupling to second-messenger pathways in the central nervous system.\(^15\)\(^,\)\(^16\) These diverse second-messenger pathways engage intracellular downstream effectors with pleiotropic consequences, such as activity-dependent structural and functional plasticity within neuroendocrine circuits that control stress and fear processes.\(^13\)\(^,\)\(^17\)\(^-\)\(^19\) Supportive of this are early examinations of rodent PACAP38 and PAC1R transcript and protein expression patterns which show both being highly expressed within brain regions known to subserve stress and fear processes.\(^11\)

**Estrogenic regulation of the PACAPergic system**

It is also important to note that \(ADCYAP1R1\) (the PAC1R gene) contains several predicted estrogen response elements (EREs).\(^20\) EREs are consensus sequences within the promoter region of target genes to which activated estrogen receptors directly bind to regulate gene transcription.\(^21\)\(^-\)\(^23\) This is important to note because levels of estradiol, one of the predominant gonadal hormones in adult females, vacillate across the female reproductive cycle. Thus, sexually mature females, PAC1R expression and PAC1R-associated functions are potentially regulated in an estrogen-dependent manner. Indeed, long-term estradiol treatment of ovariectomized female rats, via continuous release estrogen pellets, has been shown to increase \(ADCYAP1R1\) and \(ADCYAP1\) transcript expression within the bed nucleus of the stria terminalis.
In part, these results parallel earlier studies showing that brain ADCYAPI transcript levels vary across the rat estrous cycle with the greatest change occurring during proestrus—–a period characterized by peak gonadal hormones, including estradiol. Overall, these data suggest that the expression of PACAP-PAC1Rs is dynamically regulated by cycling levels of estradiol, and this dependency may confer sex-specific PACAP-PAC1R functional consequences, particularly within neural circuits of fear and stress.

**PACAP-PAC1R and the stress response**

Collectively, rodent studies indicate that the PACAPergic system is a master regulator of both central and peripheral stress responses after threat exposure. Anatomically, PACAP and PAC1R immunoreactive cells are present within stress-regulating brain regions. Furthermore, the functional consequences of this expression pattern are notable after chronic stress exposure, which results in elevated PACAP and PAC1R transcript expression in these brain regions. Similarly, other studies demonstrate that increasing central PACAP levels, via intracerebroventricular injections in behaviorally naive rats, enhance physiological hallmarks of stress, such as increased glucocorticoid release and sympathetic activation. Parallel to these results, global loss of the PACAP or PAC1Rs attenuates normal molecular, physiological, and behavioral consequences of environmental stressors, whereas manipulations of PACAP levels or PAC1R activity, specifically within stress-responsive brain regions, are accompanied by enhancement of stress-related behavioral phenotypes, such as startle responses and anxiety-like behaviors. These data not only support the role of the PACAPergic system in stress-response mechanisms, but also suggest that PACAP-PAC1R interactions are upstream of many well-known stress mediators. Altogether, these experiments demonstrate that PACAP-PAC1R functions, particularly within stress-regulating neural substrates, are principal facilitators of molecular, physiological, and behavioral consequences of stress exposure.

**Sex-dependency of PACAP-PAC1R regulation of stress responsivity**

There are few studies that have examined whether PACAP-PAC1R regulation of the stress response exhibits sex dependency. Of those, there appears to be no influence of the primary gonadal hormone in females, estradiol, on PACAP recruitment of corticosterone. However, these experiments were carried out in ovariectomized rats; therefore, additional studies, particularly in naturally cycling rodents, may offer greater translational insight into the relationship between sex and PACAP-PAC1R regulation of stress responsivity. The data discussed in the previous paragraph strongly argue that PACAP-PAC1R functions within stress-regulating brain regions—such as the amygdala, hippocampus, prefrontal cortex, and BNST—play an important role in stress responsivity to environmental threats. Notably, these brain regions are sexually dimorphic, abnormal in PTSD cohorts, and under significant gonadal hormone control, implying that within the sex-dependent constraints of these stress-regulating circuits, PACAP-PAC1R actions, or lack thereof, may confer differential sex-dependent vulnerabilities to stress-related pathologies such as PTSD, as discussed further below.

**Fear regulation as a biomarker of PTSD in humans**

Patients with PTSD, as compared with trauma-exposed controls, also exhibit abnormally high conditioned fear responses, as well as deficits in fear inhibition and extinction. These pathological fear mechanisms are hypothesized to result from either one or a combination of the following dysregulated fear-memory processes: (i) an inability to habituate to aversive environmental stimuli; (ii) impaired capacity to inhibit or extinguish fear memory; and/or (iii) an overconsolidation of the initial fear memory. To examine these dysregulated fear mechanisms, Pavlovian fear conditioning and extinction or fear inhibition behavioral paradigms extremely valuable in dissecting the pathophysiology of PTSD in preclinical and clinical have been shown to be studies. More specifically, these paradigms permit the examination of species-specific indices of fear acquisition and inhibition long after the aversive stimuli is removed from the experimental environment. Altogether, these data argue in favor of experimental models of fear learning, extinction, and inhibition as useful models for understanding PTSD pathophysiology.
Fear-memory processes and the PACAPergic system

Consistent with PACAP-PAC1R expression within neural substrates of fear-memory, functional and behavioral analyses show that PACAP-PAC1R actions also play a role in fear-memory mechanisms. Whereas global PAC1R loss, in rodent models, does not lead to deficits in declarative memory or cued-fear memory retrieval, significant deficits in contextual fear memory are observed, thereby demonstrating that PAC1R signaling plays a critical role in hippocampal-dependent fear-memory circuits. Moreover, this deficiency in context-related associative learning is also accompanied by impaired long-term synaptic plasticity in the hippocampus—a relatively long-lasting functional change in synaptic strength that is thought to represent the cellular basis for fear-memory consolidation. Similarly, hippocampal- and amygdala-specific PAC1R pharmacological inhibition attenuate contextual fear-memory recall, albeit cued-fear-memory consolidation was not assessed in this study. These experimental results suggest that PACAP-PAC1R actions are enlisted, within neural substrates of the fear-memory circuit, to promote contextual fear-learning mechanisms. Supportive of this conclusion are classical fear-conditioning studies, where a previously neutral tone paired with a series of foot shocks increased both PACAP and PAC1R transcripts in the amygdala, BNST, and prefrontal cortex of mice. Furthermore, a positive correlation found between prefrontal cortex and amygdala PAC1R transcript levels and the degree of fear learning was also observed. Altogether, these data argue that PACAP-PAC1R actions are engaged within fear-learning neural circuits to promote fear-memory consolidation and retrieval. Given the evidence of PACAP-PAC1R function as central to fear and stress processes and the deterioration of these processes in PTSD symptomatology, the PACAP-PAC1R system has emerged as an attractive candidate in the examination of PTSD susceptibility.

Peripheral PACAP levels as a biomarker for sex-specific PTSD risk

As alluded to earlier, the hallmark features of PTSD symptom clusters are maladaptive stress responsivity and fear-memory processes after trauma exposure (DSM-5). It is, therefore, unsurprising that many stress- and fear-regulating neurobiological systems, such as the PACAPergic system, are dysregulated in PTSD patients. Interestingly, dysfunctions in the PACAP-PAC1R system appear to uniquely facilitate PTSD vulnerability in sexually mature females rather than males. Relatively recently, our lab found that peripheral PACAP38 levels were positively correlated with total PTSD symptoms, specifically in adult female PTSD cohorts, with no association between peripheral PACAP38 and PTSD symptoms found in male PTSD counterparts despite males also exhibiting similarly high blood PACAP38 levels. Furthermore, peripheral PACAP38 levels were also predictive of PTSD diagnosis specifically for female, but not male, PTSD cohorts. Although differently characterized in the DSM-IV and the DSM-5, the three primary symptom clusters of PTSD, ie, intrusive re-experiencing, avoidance, and hyperarousal, were also positively correlated with peripheral PACAP38 levels in females, with higher levels of PACAP38 predictive of these subscale symptoms specifically in female, but not male, PTSD cohorts. These associations were replicated in a similar sample of highly traumatized adult females and remained statistically significant even when controlling for age, total trauma exposure, and other disorders often comorbid with PTSD, such as depression and substance abuse. Furthermore, the association between peripheral PACAP38 levels and inhibition of conditioned fear was also examined. Females with elevated PACAP38 levels demonstrated impaired inhibition of conditioned fear, as exhibited by an inability to discriminate between the conditioned stimulus (danger cue) and unconditioned stimulus (safety cue). Overall, these data suggest that blood PACAP38 levels are associated with PTSD symptoms, specifically in female cohorts.

Sex-specific genetic risk for PTSD

The significant influence of genetic factors in PTSD susceptibility is evident in twin studies, which compellingly demonstrate that genetic factors account for 30% to 70% of PTSD risk. Intriguingly, this heritability of PTSD is higher in females than males—evidence that indicates a higher contribution of heritability to PTSD vulnerability in females. Molecular studies have identified over 20 genetic polymorphisms that are more frequent in PTSD cohorts than controls (reviewed in Norholm and Ressler). However, until recently, none of the 20 PTSD-associated genetic polymorphisms were
associated with female-specific PTSD risk, despite females exhibiting greater PTSD heritability. This has made it difficult to examine how genetic variability interacts with environmental risk factors to modulate sex-specific PTSD risk.

**PAC1R genetic variability as biomarker for female-specific PTSD risk**

Taking into consideration the greater degree of heritability in PTSD vulnerability and the correlation between peripheral PACAP38 levels and PTSD symptomatology specifically in female PTSD cohorts, genetic polymorphisms in the PACAP and PAC1R loci (ADCYAPI and ADCYAPIRI, respectively) were assessed to determine whether PACAP-PAC1R genetic variability is associated with PTSD diagnosis and symptoms, as well as physiological and psychological intermediates in highly traumatized civilians. Using a tag–single-nucleotide-polymorphism (tag-SNP) approach, investigators examined 44 SNPs in ADCYAPI and ADCYAPIRI. However, only one SNP, rs2267735 in ADCYAPIRI, was found to be significantly associated with PTSD diagnosis specifically in female, but not male, PTSD subjects, including an additional cohort that served as replication source. Although genetic variations in and around ADCYAPIRI are implicated in other mental disorders, such as major depression and schizophrenia, this rs2267735 polymorphism was not associated with these and other severe psychiatric disorders, such as bipolar disorder and Alzheimer disease, implying that rs2267735 may be specifically predictive of PTSD diagnosis in adult females.

We also explored whether the ADCYAPIRI risk genotype was also predictive of PTSD symptomatology in a sex-specific manner. Moreover, analyses of the relationship between the ADCYAPIRI risk allele and PTSD symptoms revealed a replicable, dose-dependent relationship between the risk allele and total PTSD symptoms, with female “CC” carriers demonstrating greater PTSD symptoms than “CG” or “GG” carriers. Additional analyses revealed that physiological measures of stress and fear are also differentially associated with the ADCYAPIRI SNP. Even after controlling for trauma, age, and race, the ADCYAPIRI “CC” genotype was strongly associated with higher levels of hyperarousal symptoms than those observed in “CG” or “GG” female carriers. Furthermore, when we assessed physiological measures of fear, using fear-potentiated startle and dark-enhanced startle, female carriers of the “CC” genotype had impaired startle discrimination and enhanced fear responsivity, respectively, as compared with “CG” or “GG” female carriers. Intriguingly, both measures of fear responsivity are consistently impaired in PTSD cohorts.

In further support of its contributions to sex-specific PTSD risk, rs2267735 was also located within a predicted ERE of the ADCYAPIRI locus. Given the estrogen-dependency of ADCYAPIRI transcript expression and evidence of estradiol-ERE interactions in gene-expression regulation, we utilized a previously analyzed data set, with combined brain messenger RNA (mRNA) expression and genome-wide association data, to examine the functional implications of ADCYAPIRI rs2267735 on central PAC1R transcript expression. Overall, these data show that females carrying the ADCYAPIRI rs2267735 risk genotype (‘CC’) expressed significantly less cortical ADCYAPIRI mRNA than male “CC” carriers or females that did not carry the risk allele. Although additional studies are warranted, these results suggest that the “CC” risk allele potentially impairs estrogen-dependent ADCYAPIRI transcript expression, thus resulting in lower ADCYAPIRI mRNA levels. Intriguingly, the sex-dependency of the ADCYAPIRI risk genotype does not manifest until puberty, consistent with a role for cycling estrogen in its regulation. Indeed, the fear stress-regulating and anxiolytic roles of testosterone may, in part, explain why the “CC” risk allele, though associated with pathologic threat responsivity in both prepubescent males and females, is no longer predictive of PTSD diagnosis and physiological fear responses in postpubescent males. Though additional studies are needed, these collective data suggest that impaired estradiol-ERE interactions, as a result of the “CC” risk allele, may act as one of the mechanisms through which sexually mature females gain greater PTSD vulnerability.

**Neuroimaging profiles as intermediate phenotypes of sex-specific PTSD risk**

As alluded to earlier, PTSD-implicated stress- and fear-neural circuits are also sexually dimorphic. For example, healthy males and females exhibit a number of sex differences in region-specific sizes and differential neural activation patterns during fear-learning tasks and...
after exposure to stressors. Interestingly, sex differences in PTSD diagnosis, symptom duration, symptom severity, and functional impairment emerge after adolescence, a period characterized by striking changes in cycling levels of gonadal hormones. The coincidental emergence of differential PTSD vulnerability alongside the onset of gonadal hormone cyclicity suggests that activational effects of gonadal hormones, within the confines of sexually dimorphic stress- and fear-neural circuits, lead to sex-dependent differences in trauma responsivity.

In light of this, it is also important to investigate intermediate phenotypes related to the ADCYAP1R1 SNP to further understand why this risk allele, in females, is predictive of exaggerated arousal responses characteristic of PTSD psychophysiology. To do this, we used functional magnetic resonance imaging (fMRI) analyses in a sample of adult females who carried or lacked the risk allele and who have experienced a moderate to high level of civilian trauma in order to assess the consequence of the ADCYAP1R1 risk allele on amygdala and hippocampal activation, as well as the functional connectivity between the two. These brain regions were chosen as they are often implicated in PTSD pathophysiology; furthermore, it is also known that PACAP and PAC1Rs exhibit high density and facilitate synaptic plasticity, as well as additional biological functions within these brain regions.

This study found that in response to unconditioned fearful-face stimuli, females with “CC” risk alleles, as compared with females with the “GC” or “GG” non-risk alleles, demonstrate increased activation of both the amygdala and hippocampus, as well as reduced functional connectivity between the two (Figure 1). These data are consistent with previous studies that show greater fear responsivity (i.e., dark-enhanced startle) in females with the ADCYAP1R1 “CC” genotype than in “GC” or “CC” carriers. Furthermore, these activational changes within fear-regulating neural circuits are characteristic of neurobiological profiles of PTSD, suggesting that the ADCYAP1R1 “CC” risk allele increases the PTSD vulnerability profile of female carriers by dysregulating neural circuits that subserve unconditioned fear responsivity.

In comparison with unconditioned fear responses, fMRI studies revealed that contextual, but not cued, fear conditioning resulted in a gene-dose-dependent decrease

---

**Figure 1.** The ADCYAP1R1 risk allele (rs2267735) is associated with increased amygdala activation (A) and decreased amygdala-hippocampal connectivity (B) in traumatized women when viewing fearful faces (N=49).

Adapted from reference 76: Stevens JS, Almli LM, Fani N, et al. PACAP receptor gene polymorphism impacts fear responses in the amygdala and hippocampus. *Proc Natl Acad Sci U S A*. 2014;111(8):3158-3163. Copyright © National Academy of Science 2014
in hippocampal activation in female carriers of the “C” PTSD risk allele during the late acquisition of contextual fear, with no differences found during habituation, early acquisition, or extinction.\textsuperscript{83} Interestingly, these data parallel deficits in contextual, but not cued, fear learning found in mice with global PAC1R loss\textsuperscript{84} and suggest that decreased \textit{ADCYAPIRI} mRNA expression, associated with the female-specific risk genotype,\textsuperscript{20} attenuates hippocampal activation and, by extension, impairs contextual processing during fear learning. Indeed, PTSD cohorts exhibit impaired hippocampal-dependent contextual fear conditioning.\textsuperscript{85} Collectively, this work demonstrates genetic penetrance of the \textit{ADCYAPIRI} risk allele at the level of PTSD-implicated neural circuits which, in turn, manifest as intermediate phenotypes of the \textit{ADCYAPIRI} risk allele during unconditioned and conditioned fear.

\textbf{Interactions between genetic and environmental risk factors in sex-specific PTSD risk}

Twin studies provide compelling evidence that although genetic factors account for 30\% to 70\% of PTSD risk, the remaining variance in PTSD vulnerability is accounted for by individual-specific environmental exposure.\textsuperscript{86} This level of specificity implies that trauma characteristics play an important role in shaping individual PTSD risk.\textsuperscript{7} Experience of trauma, defined by the DSM-5 as having “experienced, witnessed, or [been] confronted with an event or events that involved actual or threatened death or serious injury, or a threat to the physical integrity of the self or others,” can be segregated into two broad categories. The first is systemic/neurogenic, which represents a homeostatic challenge or a physical stimulus that is recognized by somatic, visceral, or circumventricular sensory pathways and requires an immediate “systemic” reaction that is triggered by reflexive mechanisms.\textsuperscript{87} The second category is processive, which is of psychological origin and which recruits brain regions involved in higher-order processing/decision making and represents responses mounted in anticipation of, rather than in reaction to, a homeostatic threat. This type of trauma is influenced by previous experiences (eg, associative learning) or species-specific predispositions (eg, the aversion to snakes in humans) and allows the organism to detect novel stimuli that predict sources of harm.\textsuperscript{88} When activated by environmental threat, psychological trauma engages mediators in the corticolimbic circuitry that subserve decision making, learning, and memory, as well as emotionality. However, it is important to note that though both types of trauma theoretically recruit distinct neural circuits, at times, trauma types are not entirely separable, as physical stressors may, to varying

\begin{itemize}
  \item \textbf{Figure 2.} Schematic illustrating the proposed relationship between pituitary adenylate cyclase–activating polypeptide (PACAP)–PAC1 receptor (PAC1R) signaling and fear/stress processes elicited by trauma exposure. (\textbf{Left}) The predominant gonadal hormone in females, estradiol (E\textsubscript{2}), and trauma both regulate the PACAP-PAC1R system in the female brain to drive normal fear and stress processes. (\textbf{Right}) Females, but not males, with high plasma PACAP38 levels and PAC1R polymorphisms may have altered PACAP-PAC1R signaling, which consequently drives pathological fear and stress processes associated with posttraumatic stress disorder (PTSD). This schematic diagram suggests that the responsiveness of the PACAP-PAC1R system to E\textsubscript{2} might be important in regulating PACAP-PAC1R activation of fear- and stress-dependent pathways and phenotypes that underlie the sex-bias in PTSD prevalence. ERE, estrogen responsive element; E\textsubscript{2}, estradiol; Trauma, psychological trauma; PACAP, pituitary adenylate cyclase–activating polypeptide.
\end{itemize}
degrees, have psychosocial facets and vice versa. Nonetheless, these distinct differences in trauma features may confer differential interactions between environmental and genetic risk factors and, as a result, confer differential PTSD vulnerabilities.

Though the effects of trauma characteristics on sex-specific PTSD risk are not as clear, differences in PTSD vulnerability may, partly, be due to differences in specific trauma types to which each sex is exposed. Indeed, females experience higher rates of sexual trauma than males, who in general experience higher rates of trauma, as well as higher rates of nonsexual assaults and physical violence. Thus, it is possible that males and females engage different trauma-related neural processes more frequently.

**PACAP signaling is required for biological responsivity to psychological trauma**

Given that females have a higher exposure rate to psychological trauma and are predisposed to PACAP-PAC1R PTSD risk factors, it is also interesting to note that, in rodent models, the trauma type (psychological vs physical) also appears to differentially recruit the PACAPergic system. This is partly demonstrated in transgenic mice that globally lack PACAP protein (PACAP-knockout mice). PACAP-knockout mice, as compared with controls, demonstrate blunted hypothalamic-pituitary-adrenal (HPA) axis activation and impaired stress-coupled molecular activity after psychological stressors, such as restraint stress, light exposure after constant dark, or open field exposure. Contrarily, global loss of PACAP does not impair HPA activation, as measured by plasma corticosterone levels, after systemic/neurogenic stressors, such as immune, metabolic, or cold-exposure challenges. These data suggest that, unlike physical stressors, psychological stressors depend on PACAP signaling to recruit molecular and neuroendocrine processes. Though additional studies are needed, these data collectively indicate that the prevalence of psychological stress exposure in female cohorts may lead to a greater dependence on PACAP-mediated biological responsivity in females than in males, after environmental trauma exposure. Thus, impairment of the PACAPergic system and, in turn, an inadequate stress response to environmental threats—a risk factor for PTSD—will have greater pathological consequences for females.

There also appears to be a within-trauma-type effect of trauma persistence on PTSD vulnerability. In mice, the PACAP-dependence of HPA axis activation after psychological stressors is consistently greater for prolonged trauma than for acute psychological trauma. In support of this, associations between the *ADCYAP1R* rs2267735 risk allele and childhood maltreatment—one of the most robust environmental risk factors for PTSD among trauma-exposed adults—were moderated by the number of exposures to childhood maltreatment (CM) in female PTSD, but not depression, cohorts. Moreover, CM-exposed females carrying one or more of the *ADCYAP1R* “C” alleles showed increased risk for PTSD, as well as greater PTSD severity. These data suggest a within-trauma-type effect of the PACAPergic system after psychological trauma.

**Conclusions**

The PACAP and PAC1R systems serve as a system-wide mediator of stress responses. Convergent animal and human data suggest a robust role for this system within neural nodes that regulate stress and fear processes elicited by trauma exposures. Furthermore, data from multiple sources now suggest a role for dysregulated PACAP-PAC1R in PTSD. Notably, in humans, this effect seems most robust in females and increasing data suggest that this is due to estrogenic regulation of the *ADCYAP1R* gene in combination with the sex-specific dominance of trauma type recruiting stress and fear processes (Figure 2). There are also compelling data for significant interactions between the *ADCYAP1R* risk allele and persistence of childhood maltreatment in female PTSD cohorts. These data indicate that trauma amount differentially interacts with PAC1R genetic risk factors and may reflect a greater impact of PAC1R dysfunction under conditions where its recruitment is crucial for effective physiological and psychological responses to trauma. Much is yet to be learned about the role of sex biology, estrogen regulation, and PACAP-PAC1R functions, but these may make up one of the more robust “sex x environment interactions” models in understanding brain function related to sex, trauma, and PTSD.

**Acknowledgments/Conflict of Interest:** Research in the author’s laboratories is supported by funds from R01 MH096764 and R01 MH108665. The authors have no conflicts of interest to disclose.
PTSD, PACAPergic system, and sex differences - Ramikie and Ressler

REFERENCES

1. Bangasser DA, Valentino RJ. Sex differences in stress-related psychiatric disorders: neurobiological perspectives. Front Neurol. 2014;5(350):293-319.

2. Breslau N, Davis GC, Peterson EL, Schultz L. Psychiatric sequelae of posttraumatic stress disorder in women. Arch Gen Psychiatry. 1997;54(1):81-87.

3. Alim TN, Graves E, Mellen TA, et al. Trauma exposure, posttraumatic stress disorder and depression in an African-American primary care population. J Natl Med Assoc. 2006;98(10):1630-1636.

4. Resnick HS, Kilpatrick DG, Dansky BS, Saunders BE, Best CL. Prevalence of civilian trauma and posttraumatic stress disorder in a representative national sample of women. J Consult Clin Psychol. 1993;61(6):984-991.

5. Pynoos RS, Frederick C, Nader K, et al. Life threat and posttraumatic stress in school-age children. Arch Gen Psychiatry. 1987;44(12):1057-1063.

6. Sartor CE, McCutcheon VV, Pommer NE, et al. Common genetic and environmental contributions to posttraumatic stress disorder and alcohol dependence in young women. Psychol Med. 2011;41(7):1497-1505.

7. Stein MB, Jang KL, Taylor S, Vernon PA, Livesley WJ. Genetic and environmental influences on trauma exposure and posttraumatic stress disorder symptoms: a twin study. Am J Psychiatry. 2002;159(10):1675-1681.

8. Dias BG, Ressler KJ. PACAP and the PAC1 receptor in post-traumatic stress disorder. Neuropsychopharmacology. 2013;38(1):245-246.

9. Vaudry D, Falluel-Morel A, Bourgault S, et al. Pituitary adenylate cyclase-activating polypeptide and its receptors: 20 years after the discovery. Pharmacol Rev. 2009;61(3):283-357.

10. Miyata A, Jiang L, Dahl RD, et al. Isolation of a neuropeptide corresponding to the N-terminal 27 residues of the pituitary adenylate cyclase-activating peptide with 38 residues (PACAP38). Biochem Biophys Res Commun. 1990;170(2):643-648.

11. Arimura A, Somogyvari-Vigh A, Miyata A, Mizuno K, Coy DH, Kitada C. Tissue distribution of PACAP as determined by RIA: highly abundant in the rat brain and testes. J Biol Chem. 1990;265(2):643-648.

12. Joo KM, Chung YH, Kim MK, et al. Distribution of vasoactive intestinal polypeptide and pituitary adenylate cyclase-activating polypeptide receptors (VPAC1, VPAC2, and PAC1 receptor) in the brain. J Comp Neurol. 2004;476(4):389-413.

13. Shivers BD, Gorcs TJ, Gottschall G, et al. Two high affinity binding sites for pituitary adenylate cyclase-activating polypeptide have different tissue distributions. Endocrinology. 1991;128(6):3055-3065.

14. Spengler D, Waerber C, Pantalone C, et al. Differential signal transduction by five splice variants of the PACAP receptor. Nature. 1993;365(6442):170-175.

15. Ajpru S, McArthur AJ, Piggins HD, Sugden D. Identification of PAC1 receptor isoform mRNAs by real-time PCR in rat suprachiasmatic nucleus. Brain Res Mol Brain Res. 2002;105(1-2):29-37.

16. Pulizer J, Gozes I. VIP provides cellular protection through a specific splice variant of the PACAP receptor: a new neuroprotection target. Peptides. 2006;27(11):2867-2876.

17. Kondo T, Tominaga T, Ichikawa M, Iijima T. Differential alteration of hippocampal synaptic strength induced by pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38). Neurosci Lett. 1997;221(2-3):189-192.

18. Tye KM, Deisseroth K. Optogenetic investigation of neural circuits underlying brain disease in animal models. Nat Rev Neurosci. 2012;13(4):251-266.

19. Tye KM, Prakash R, Kim SY, et al. Amygdala circuitry mediating reversible and bidirectional control of anxiety. Nature. 2011;471(7338):358-362.

20. Ressler KJ, Mercer KB, Bradley B, et al. Post-traumatic stress disorder is associated with PACAP and the PAC1 receptor. Nature. 2011;470(7355):492-497.

21. Driscoll MD, Sathyam S, Muyan M, Klink CM, Hilf R, Bambara RA. Sequence requirements for estrogen receptor binding to estrogen response elements. J Biol Chem. 1998;273(45):29321-29330.

22. Heldring N, Pike A, Andresson S, et al. Estrogen receptors: how do they signal and what are their targets. Physiol Rev. 2007;87(3):905-931.

23. Klinger CM. Estrogen receptor interaction with estrogen response elements. Nucl Acids Res. 2001;29(14):2905-2915.

24. Moore JP Jr, Burger LL, Dalkin AC, Winters SJ. Pituitary adenylate cyclase activating polypeptide messenger RNA in the paraventricular nucleus and anterior pituitary during the rat estrous cycle. Biol Reprod. 2005;73(3):491-499.

25. Fata JE, Chaudhary V, Khokha R. Cellular turnover in the mammary gland is correlated with systemic levels of progesterone and not 17β-estradiol during the estrous cycle. Biol Reproduction. 2001;65(3):680-688.

26. Hammack SE, May V. Pituitary adenylate cyclase activating polypeptide in stress-related disorders: data convergence from animal and human studies. Biol Psychiatry. 2015;78(3):167-177.

27. Missig G, Roman CW, Vizzardi MA, Braas KM, Hammack SE, May V. Parabrachial nucleus (PBN) pituitary adenylate cyclase activating polypeptide (PACAP) signaling in the amygdala: implication for the sensory and behavioral effects of pain. Neuropharmacology. 2014;86:38-48.

28. Condore MC, Matynia A, Foster NN, et al. High-resolution characterization of a PACAP-EGFP transgenic mouse model for mapping PACAP-expressing neurons. J Comp Neural. 2016 May 14. Epub ahead of print. doi:10.1002/cne.24035.

29. Goosens KA. Hippocampal regulation of averse memories. Curr Opin Neuropsi. 2011;21(3):460-466.

30. Hammack SE, Cheung J, Rhodes KM, et al. Chronic stress increases pituitary adenylate cyclase-activating peptide (PACAP) and brain-derived neurotrophic factor (BDNF) mRNA expression in the bed nucleus of the stria terminals (BNST); roles for PACAP in anxiety-like behavior. Psychoendoendocrinology. 2009;34(6):833-843.

31. Tanida N, Shintani N, Morita Y, et al. Regulation of autonomic nerve activities by central pituitary adenylate cyclase-activating polypeptide. Regul Pept. 2010;161(1-3):73-80.

32. Agarwal A, Halvorson LM, Legradi G. Pituitary adenylate-cyclase activating polypeptide (PACAP) mimics neuroendocrine and behavioral manifestations of stress: evidence for PCA-mediated expression of the corticotropin-releasing hormone (CRH) gene. Brain Res Mol Brain Res. 2005;73(1):45-57.

33. Drewe R, Iemoio A, Smith KL, Wang X, Cottone P, Sabino V. CRF mediates the anxiogenic and anti-rewarding, but not the anorectic effects of PACAP. Neuropharmacology. 2013;68:2160-2169.

34. Stroth N, Liu Y, Aguileria G, Eiden LE. Pituitary adenylate cyclase-activating polypeptide controls stimulus-transcription coupling in the hypothalamic-pituitary-adrenal axis to mediate sustained hormone secretion during stress. J Neuroendocrinol. 2011;23(10):944-955.

35. Roman CW, Lezak KR, Hartsock MJ, et al. PAC1 receptor antagonism in the bed nucleus of the stria terminals (BNST) attenuates the endocrine and behavioral consequences of chronic stress. Psychoneuroendocrinology. 2014;47:151-165.

36. Lehmann ML, Mustafa T, Eiden AM, Herkenham M, Eiden LE. PACAP-deficient mice show attenuated corticosterone secretion and fail to develop depressive behavior during chronic social defeat stress. Psychoneuroendocrinology. 2013;38(5):702-715.

37. Mustafa T, Jiang S, Eiden AM, Weihe E, Thistlethwaite I, Eiden LE. Impact of PACAP and PAC1 receptor deficiency on the neurochemical and behavioral effects of acute and chronic restraint stress in male C57BL/6 mice. Stress. 2015;18(4):408-418.

38. Lezak KR, Roelke E, Harris OM, et al. Pituitary adenylate cyclase-activating polypeptide (PACAP) in the bed nucleus of the stria terminals (BNST) increases corticosterone in male and female rats. Psychoneuroendocrinology. 2014;45:11-20.

39. Sabatinielli D, Fortune EE, Li Q, et al. Emotional perception: meta-analyses of face and natural scene processing. Neuroimage. 2011;54(3):2524-2533.

40. Phan KL, Wager TD, Taylor SF, Liberzon I. Functional neuroimaging studies of human emotions. CNS Spectr. 2004;9(4):258-266.

41. Phan KL, Taylor SF, Welsh RC, Ho SH, Britton JC, Liberzon I. Neural correlates of individual ratings of emotional salience: a trial-related fMRI study. Neuroimage. 2004;21(2):768-780.

42. Admon R, Lubin G, Rosenblatt JD, et al. Imbalanced neural responsivity to risk and reward indicates stress vulnerability in humans. Cereb Cortex. 2013;23(1):28-35.
Translational research

43. Shivi E, Sullivan GM, Schafer S, et al. Sex differences in extinction recall in posttraumatic stress disorder: a pilot fMRI study. *Neurobiol Learn Mem.* 2014;113:101-108.

44. Morey LC, Benson KT. An investigation of adherence to diagnostic criteria, revisited: clinical diagnosis of the DSM-IV/DSM-5 section II personality disorders. *J Pers Disord.* 2016;30(1):130-144.

45. Morey FR, Fernandez-Marmiesse A, Castaineras D, Fraga JM, Couce ML, Cocho JA. Corrigendum to “A glimpse into past, present, and future DNA sequencing” [Mol. Genet. Metab. 110 (2013) 3-24]. *Mol. Genet. Metab.* 2015;114(3):484.

46. Lissek S, Powers AS, McClure EB, et al. Classical fear conditioning in the anxiety disorders: a meta-analysis. *Behav Res Ther.* 2005;43(13):1391-1424.

47. Jovanovic T, Ely T, Fani N, et al. Reduced neural activation during an inhibition task is associated with impaired fear inhibition in a traumatized civilian sample. *Cogn. Neurosci.* 2013;7(7):1864-1891.

48. Jovanovic T, Norrholm SD, Blanding NQ, et al. Impaired fear inhibition is a biomarker of PTSD but not depression. *Depress. Anxiety.* 2010;27(3):244-251.

49. Jovanovic T, Norrholm SD, Fennell JE, et al. Posttraumatic stress disorder may be associated with impaired fear inhibition: relation to symptom severity. *Psychiatry Res.* 2009;167(1-2):151-160.

50. Norrholm SD, Jovanovic T, Olin IW, et al. Fear extinction in traumatized civilians and posttraumatic stress disorder: relation to symptom severity. *Biol. Psychiatry.* 2011;69(6):556-563.

51. Pitman RK, Rasmusson AM, Koenen KC, et al. Biological basis of posttraumatic stress disorder. *Nat Rev Neurosci.* 2012;13(11):769-787.

52. Graham EM, Milad MR. Blockade of estrogen by hormonal contraceptives impairs fear extinction in female rats and women. *Biol. Psychiatry.* 2013;73(4):371-378.

53. Glover EM, Jovanovic T, Mercer KB, et al. Estrogen levels are associated with extinction deficits in women with posttraumatic stress disorder. *Biol. Psychiatry.* 2012;72(1):19-24.

54. Rasmusson AM, Charney DS. Animal models of relevance to PTSD. *Ann N Y Acad Sci.* 1997;82(1):332-351.

55. Otto C, Kovalchuk Y, Wolfer DP, et al. Impairment of mossy fiber long-term potentiation and associative learning in pituitary adenylate cyclase activating polypeptide type I receptor-deficient mice. *J. Neurosci.* 2001;21(15):5520-5527.

56. Cho JH, Deisseroth K, Bolshakov VY. Synaptic encoding of fear extinction in mPFC-amygdala circuits. *Neuron.* 2013;80(6):1491-1507.

57. Schmidt SD, Milad MR. Postsynaptically expressed potentiation in the intra-amygdala circuit. *Annu. Rev. Neurosci.* 2013;36:1-23.

58. Lissek S, Powers AS, McClure EB, et al. Classical fear conditioning in the anxiety disorders: a meta-analysis. *Behav Res Ther.* 2005;43(3):261-266.

59. Zeidman MA, Igoe SA, Linman C, et al. Estradiol modulates medial prefrontal cortex and amygdala activity during fear extinction in women and female rats. *Biol. Psychiatry.* 2011;70(10):920-927.

60. Goldstein JM, Jerram M, Abbas B, Whitfield-Gabrielli S, Makris N. Sex differences in stress response circuitry activation dependent on female hormonal cycle. *J. Neurosci.* 2010;30(2):431-438.

61. Breslau N, Davis GC, Andriske P, Peterson EL, Schultz LR. Sex differences in posttraumatic stress disorder. *Arch. Gen. Psychiatry.* 1997;54(11):1044-1048.

62. Seeman MV. Psychopathology in women and men: focus on female hormones. *Am J Psychiatry.* 1997;154(12):1641-1647.

63. Stevens JS, Almli LM, Fani N, et al. PACAP receptor gene polymorphism impacts fear responses in the amygdala and hippocampus. *Proc. Natl Acad. Sci. U S A.* 2014;111(8):3158-3163.

64. Dannlowski U, Kugel H, Huber F, et al. Childhood maltreatment is associated with an automatic negative emotion processing bias in the amygdala. *Hum Brain Mapp.* 2013;34(11):2899-2909.

65. Cho JH, Zushida K, Shumyatsky GP, Carlezen WA Jr, Meloni EG, Bolshakov VY. Pituitary adenylate cyclase-activating polypeptide induces postsynaptically expressed potentiation in the intra-amygdala circuit. *J. Neurosci.* 2012;32(41):14165-14177.

66. Yang K, Lei G, Jackson MF, Macdonald JP. The involvement of PACAP/ VIP system in the synaptic transmission in the hippocampus. *J. Mol. Neurosci.* 2010;42(3):319-326.

67. Lindholm D, Skogloisa Y, Taki N. Developmental regulation of pituitary adenylate cyclase activating polypeptide (PACAP) and its receptor 1 in rat brain: function of PACAP as a neurotrophic factor. *Annu. N.Y. Acad. Sci.* 1998;865:189-196.

68. Stevens JS, Jovanovic T, Fani N, et al. Disrupted amygdala-prefrontal functional connectivity in civilian women with posttraumatic stress disorder. *J. Psychiath Res.* 2013;47(10):1469-1478.

69. Rauch SL, Whalen PJ, Shin LM, et al. Exaggerated amygdala response to masked facial stimuli in posttraumatic stress disorder: a functional MRI study. *Biol. Psychiatry.* 2000;47(9):769-776.

70. Pohllack ST, Nees F, Ruttorf M, et al. Neural mechanism of a sex-specific risk variant for posttraumatic stress disorder in the type I receptor of the pituitary adenylate cyclase activating polypeptide. *Biol. Psychiatry.* 2015;78(2):840-847.

71. Panthong A, Kanjanapothi D, Taeotikul T, Phankummoon A, Panthong K, Reutrakul V. Anti-inflammatory activity of methanolic extracts from *Vitellago hamardiana Pierre.* *J. Ethnopharmacol.* 2004;91(2-3):237-242.

72. Brewin CR, The nature and significance of memory disturbance in posttraumatic stress disorder. *Annu. Rev. Clin. Psychol.* 2011;7:203-227.

73. Lyons MJ, Goldberg J, Eisen SA, et al. Do genes influence exposure to trauma? A twin study of combat. *Am J Med Genet.* 1993;48(1):22-27.

74. Herman JP. Neural control of chronic stress adaptation. *Front Behav. Neurosci.* 2013;7:61.

75. Ohman A, Mineka S. Fears, phobias, and preparedness: toward an evolved module of fear and fear learning. *Psychol. Rev.* 2001;108(3):483-522.

76. Joels M, Baram TZ. The neuro-symphony of stress. *Nat Rev. Neurosci.* 2009;10(6):459-466.
90. Ursano RJ, Fullerton CS, Epstein RS, et al. Acute and chronic post-traumatic stress disorder in motor vehicle accident victims. *Am J Psychiatry.* 1999;156(4):589-595.

91. Walker JL, Carey PD, Mohr N, Stein DJ, Seedat S. Gender differences in the prevalence of childhood sexual abuse and in the development of pediatric PTSD. *Arch Womens Ment Health.* 2004;7(2):111-121.

92. Olff M, Langeland W, Draijer N, Gersons BP. Gender differences in posttraumatic stress disorder. *Psychol Bull.* 2007;133(2):183-204.

93. Marmar CR, Weiss DS, Schlenger WE, et al. Peritraumatic dissociation and posttraumatic stress in male Vietnam theater veterans. *Am J Psychiatry.* 1994;151(6):902-907.

94. Hatanaka M, Tanida M, Shintani N, et al. Lack of light-induced elevation of renal sympathetic nerve activity and plasma corticosterone levels in PACAP-deficient mice. *Neurosci Lett.* 2011;444(2):368-375.

95. Yehuda R, Southwick SM, Krystal JH, Bremner D, Charney DS, Mason JW. Enhanced suppression of cortisol following dexamethasone administration in posttraumatic stress disorder. *Am J Psychiatry.* 1993;150(1):83-86.

96. Brewin CR, Andrews B, Valentine JD. Meta-analysis of risk factors for posttraumatic stress disorder in trauma-exposed adults. *J Consult Clinical Psychol.* 2000;68(5):748-766.

97. Ozer EJ, Best SR, Lipsey TL, Weiss DS. Predictors of posttraumatic stress disorder and symptoms in adults: a meta-analysis. *Psychol Bull.* 2003;129(1):52-73.

98. Uddin M, Chang SC, Zhang C, et al. ADCYAP1R1 genotype, posttraumatic stress disorder, and depression among women exposed to childhood maltreatment. *Depress Anxiety.* 2013;30(3):251-258.